Be the Future of Food Allergy Research: Join the FARE Patient Registry

The FARE Patient Registry marks its first-year anniversary today. We’re celebrating this milestone by encouraging food allergy patients (or their legal representatives) to join the registry’s clinical trial.

The registry is a platform that connects people living with food allergy to researchers looking for solutions. Participants answer survey questions about their experiences with diagnosed food allergy. The registry collects and organizes these patient experiences in a privacy-protected online database. Investigators can then search the de-identified (anonymous) data to find hidden patterns and make new discoveries, while enrolled patients can gain new perspectives on food allergy by viewing the anonymous data shared by registry members.

In only one year’s time, the FARE Patient Registry is already the largest repository of patient-provided food allergy data. Nearly 5,000 patients, ranging in age from infants to senior citizens, have already enrolled in the registry’s demographic study. Future plans to expand the registry include receiving de-identified clinical data from the 30 food allergy centers in the FARE Clinical Network, sharing registry data among FARE Clinical Network research programs, and using the registry to connect patients and researchers for clinical trials.

Any person living anywhere with a diagnosed or well-documented medical history of food allergy can be part of the FARE Patient Registry. The registry’s study includes 190 food allergens and can accommodate any language compatible with Google Translate. As more individuals enroll in the registry study, the data becomes more useful to researchers, helping to characterize the extent of the food allergy problem, including allergies to specific foods, and to define different forms and subtypes of this complex disorder.

INVEST 5-15 MINUTES IN THE FUTURE OF FOOD ALLERGY RESEARCH:

JOIN THE FARE PATIENT REGISTRY TODAY!

FARE’s mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. Initiatives that support this mission, like the FARE Patient Registry, are made possible in part through our partnerships with sponsors. Each of the generous sponsors quoted below recognizes the value of this unique resource for future food allergy research.

Aimmune Therapeutics ​​​​​​

"Since its launch a year ago, the FARE Patient Registry has harnessed the collective strength of the food allergy community to build an increasingly powerful tool that will help advance food allergy research. All of us at Aimmune share FARE’s commitment to improving the lives of those affected by food allergies, and we are proud to support this important collaboration. We are grateful to FARE for its visionary leadership in this effort and congratulate everyone involved in achieving this meaningful milestone."

DBV Technologies

“The FARE Patient Registry is an important contribution to advancing our understanding of food allergy diseases. We believe the information collected by this powerful network can help better assess the impact of living with a food allergy, advance clinical research and improve support for patients suffering from these diseases. We believe this registry will empower the food allergy community, and we are proud to be a sponsor of this effort.” - Dr. Todd Green, VP Medical Affairs, DBV Technologies

Sanofi S.A.

“We congratulate FARE as it marks the first anniversary of the FARE Patient Registry. This tool provides researchers with access to data that may shed light on many unanswered questions about this complex condition. As sponsors, we are proud to be part of this important step forward in the journey to provide new treatment options and hope to people living with food allergies.”

FARE gratefully acknowledges the support of Aimmune Therapeutics, DBV Technologies and Sanofi S.A. We also thank the Executive Committee of FARE’s Clinical Advisory Board for their insight, guidance and expertise.

Add new comment